Probability of Developing Schizophrenia

Schizophrenia has a lifetime prevalence of approximately 0.7% worldwide, affecting about 2.8 million adults in the United States. It typically emerges in late adolescence to early adulthood, with men tending to develop symptoms slightly earlier (late teens to early 20s) than women (late 20s to early 30s).

The causes are complex, involving an interaction of genetic vulnerability and environmental factors. Heritability is estimated at about 80%. Having a first-degree relative with schizophrenia increases risk to about 10%, and having an identical twin with the condition raises it to roughly 50%. Environmental risk factors include complications during pregnancy or birth, childhood trauma, cannabis use during adolescence, urban upbringing, and migration/social adversity.

Modern antipsychotic medications can effectively manage positive symptoms (hallucinations, delusions) in about 70-80% of patients, though negative symptoms (social withdrawal, flat affect, lack of motivation) remain harder to treat. Clozapine is the most effective antipsychotic for treatment-resistant cases. Psychosocial interventions including supported employment, cognitive remediation, and family therapy significantly improve functional outcomes. With comprehensive treatment, many patients achieve substantial recovery.